These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28482357)

  • 1. Systemic sclerosis induced by interferon-alfa treatment of melanoma.
    Silva JL; Faria DS; Teixeira F; Afonso MC; Peixoto D
    Acta Reumatol Port; 2017; 42(3):263-264. PubMed ID: 28482357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute rhabdomyolysis as a complication of interferon treatment for stage IIIc melanoma.
    Gavigan G; McEvoy A; Young V
    J Cutan Med Surg; 2014; 18(4):277-9. PubMed ID: 25008446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early signs of liver failure after low-dose interferon alfa-2b for cutaneous melanoma.
    Ammoury A; El Sayed F; Farah C; Bazex J
    J Am Acad Dermatol; 2008 Mar; 58(3):532-3. PubMed ID: 18280369
    [No Abstract]   [Full Text] [Related]  

  • 4. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
    Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
    Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute rhabdomyolysis after concurrent administration of interleukin-2, interferon-alfa, and chemotherapy for metastatic melanoma.
    Anderlini P; Buzaid AC; Legha SS
    Cancer; 1995 Aug; 76(4):678-9. PubMed ID: 8625165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed wound healing following treatment with low-dose interferon alfa-2b for cutaneous melanoma.
    Ammoury AF; El Sayed F; Bazex J
    Arch Dermatol; 2007 Oct; 143(10):1339-40. PubMed ID: 17938359
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma.
    Vallés L; González M; Polo I; Enguita AB; Vanaclocha F; Ortiz-Romero PL
    Arch Dermatol; 2009 Jan; 145(1):98-9. PubMed ID: 19153363
    [No Abstract]   [Full Text] [Related]  

  • 8. Grand mal seizure induced by interferon-alpha-2b.
    Kors C; Milling A; Hofmann M; Sterry W; Trefzer U
    J Eur Acad Dermatol Venereol; 2006 Apr; 20(4):473-4. PubMed ID: 16643159
    [No Abstract]   [Full Text] [Related]  

  • 9. Radiation recall dermatitis from high-dose interferon alfa-2b.
    Thomas R; Stea B
    J Clin Oncol; 2002 Jan; 20(1):355-7. PubMed ID: 11773198
    [No Abstract]   [Full Text] [Related]  

  • 10. Livedo reticularis associated with interferon alpha therapy in two melanoma patients.
    Ruiz-Genao DP; García-F-Villalta MJ; Hernández-Núñez A; Ríos-Buceta L; Fernández-Herrera J; García-Díez A
    J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):252-4. PubMed ID: 15752306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma.
    Kirkwood JM; Resnick GD; Cole BF
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S16-23. PubMed ID: 9122729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma.
    Wong SF; Jakowatz JG; Taheri R
    Clin Ther; 2005 Dec; 27(12):1942-8. PubMed ID: 16507380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyrotoxicosis with pegylated interferon alfa-2b.
    Lowndes SA; Asher R; Middleton MR
    Arch Dermatol; 2010 Nov; 146(11):1273-5. PubMed ID: 21079065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Livedo reticularis: a side effect of interferon therapy in a pediatric patient with melanoma.
    Fox M; Tahan S; Kim CC
    Pediatr Dermatol; 2012; 29(3):333-5. PubMed ID: 21575046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-induced cutaneous sarcoidosis in melanoma.
    Suárez-García C; Pérez-Gil A; Pereira-Gallardo S; Codes-Villena M; García-Escudero A; Miguel Camacho F
    Melanoma Res; 2009 Dec; 19(6):391-4. PubMed ID: 19770687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
    Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
    Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bilateral retinal microangiopathy in interferon therapy of malignant melanoma of the skin].
    Neubauer AS; Hoops JP
    Klin Monbl Augenheilkd; 2000 Nov; 217(5):308-11. PubMed ID: 11146832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
    Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
    J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral juxtapapillary choroidal neovascularisation associated with interferon alfa treatment of a metastatic cutaneous melanoma.
    Garcia-Arumi J; Morral Palau M; Montolio Gil M; Blasco Garrido H; Sararols Ramsay L; Segura García A
    Br J Ophthalmol; 2006 Apr; 90(4):516-8. PubMed ID: 16547342
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.